Performance of Simple Fibrosis Score in Non-Alcoholic Fatty Liver Disease with and without Type 2 Diabetes

被引:5
|
作者
Chung, Seung Min [1 ]
Kang, Min Kyu [2 ]
Moon, Jun Sung [1 ,3 ]
Park, Jung Gil [2 ,4 ]
机构
[1] Yeungnam Univ, Div Endocrinol & Metab, Coll Med, Daegu, South Korea
[2] Yeungnam Univ, Dept Internal Med, Div Gastroenterol & Hepatol, Coll Med, Daegu, South Korea
[3] Yeungnam Univ, Dept Internal Med, Div Endocrinol & Metab, Coll Med, 170 Hyeonchung Ro, Daegu 42415, South Korea
[4] Yeungnam Univ, Dept Internal Med, Div Gastroenterol & Hepatol, Coll Med, 170 Hyeonchung Ro, Daegu 42415, South Korea
关键词
Diabetes mellitus; Non-alcoholic fatty liver disease; Liver cirrhosis; Diagnostic screening programs;
D O I
10.3803/EnM.2022.1635
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This cross-sectional study enrolled 267 patients with metabolic risk factors and established non-alcoholic fatty liver disease in the prospective cohort. The performance of fibrosis-4 (FIB-4) score (>= 1.3) to diagnose advanced fibrosis using transient elastography (liver stiffness measurement [LSM] >= 8 kPa) was analyzed. Comparing patients with type 2 diabetes (T2D, n=87) and without (n=180), not FIB-4, but LSM was significantly higher in T2D (P=0.026). The prevalence of advanced fibrosis was 17.2% in T2D and 12.8% in non-T2D. FIB-4 exhibited higher proportion of false negatives in T2D patients (10.9%) than those without (5.2%). The diagnostic performance of FIB-4 was suboptimal in T2D (area under curve [AUC], 0.653; 95% confidence interval [CI], 0.462 to 0.844) compared to that in non-T2D (AUC, 0.826; 95% CI, 0.724 to 0.927). In conclusion, patients with T2D might be beneficial to conduct transient elastography without screening to avoid missing advanced fibrosis.
引用
收藏
页码:277 / 281
页数:5
相关论文
共 50 条
  • [1] Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes
    Lakhan, Manpreet
    Denning, Michael
    Varughese, George I.
    Varadhan, Lakshminara-Yanan
    DIABETES, 2011, 60 : A684 - A684
  • [2] Comparing the performance of Fibrosis-4 and Non-Alcoholic Fatty Liver Disease Fibrosis Score with transient elastography scores of people with non-alcoholic fatty liver disease
    Cox, Ben
    Trasolini, Roberto
    Gaits, Ciaran
    Yoshida, Eric M.
    Marquez, Vladimir
    CANADIAN LIVER JOURNAL, 2021, 4 (03): : 275 - 282
  • [3] Non-alcoholic fatty liver disease and type 2 diabetes mellitus: issues of the liver fibrosis diagnostics
    Anisonyan, A., V
    Sandler, Yu G.
    Khaimenova, T. Yu
    Keyan, V. A.
    Saliev, K. G.
    Sbikina, E. S.
    Vinnitskaya, E. V.
    TERAPEVTICHESKII ARKHIV, 2020, 92 (08) : 73 - 78
  • [4] Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis
    Gisondi, P.
    Barba, E.
    Girolomoni, G.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (02) : 282 - 287
  • [6] Non-alcoholic fatty liver disease and type 2 diabetes: An update
    Lee, Chi-H
    Lui, David T. W.
    Lam, Karen S. L.
    JOURNAL OF DIABETES INVESTIGATION, 2022, 13 (06) : 930 - 940
  • [7] Non-alcoholic fatty liver disease and type 2 diabetes mellitus
    Par Alajos
    Wittmann Istvan
    Par Gabriella
    ORVOSI HETILAP, 2022, 163 (21) : 815 - 825
  • [8] Fasting hyperglucagonaemia in patients with non-alcoholic fatty liver disease with and without type 2 diabetes
    Junker, A. E.
    Gluud, L.
    Knop, F. K.
    Holst, J. J.
    Vilsboll, T.
    DIABETOLOGIA, 2014, 57 : S251 - S251
  • [9] Non-alcoholic fatty liver disease and risk of type 2 diabetes
    Lallukka, S.
    Yki-Jarvinen, H.
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 30 (03) : 385 - 395
  • [10] Non-alcoholic fatty liver disease and type 2 diabetes mellitus
    Par Alajos
    Wittmann Istvan
    Par Gabriella
    ORVOSI HETILAP, 2022, 163 (22) : 855 - 862